Physicians receiving industry payments boast higher rates of brand-name prescribing: 5 points

Megan Wood -   Print  |

Boston-based Harvard Medical School researchers analyzed the connection between physician payments and higher rates of brand-name drug prescribing, according to ProPublica.

JAMA Internal Medicine published the study.

 

Here are five points:

 

1. The study found industry payments to Massachusetts physicians correlated with higher brand-name drug prescriptions for high cholesterol.

 

2. A physician's brand-name statin prescribing rate increased 0.1 percent for every $1,000 in industry payment.

 

3. Brand-name statins exceed generics cost by two to four times.

 

4. The researchers clarified many factors impact the brand-name prescribing rates, and they are not suggesting a causal relationship.

 

5. The study authors hope the results will push for reduced industry influence.

 

More articles on practice management:
How many PAs, NPs do medical practices typically employ? 5 statistics
Is a little patient mistrust always a bad thing? 4 thoughts
FDA panel supports mandatory opioid training for physicians — 5 findings from the FDA's ER/LA REMS assessments

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers